What is Maxim Group's Estimate for KindlyMD Q2 Earnings?

Key Points

• Maxim Group expects KindlyMD to post a Q2 2026 EPS loss of $0.41 and keeps a Buy rating with a $30 price target on the stock.
• The firm’s outlook still points to losses in the near term, but Maxim’s longer-range estimates suggest a possible move toward profitability in parts of fiscal 2027.
• KindlyMD’s latest reported quarter showed a much larger-than-expected EPS loss of $15.20 on $2.68 million in revenue, underscoring ongoing profitability challenges.

KindlyMD, Inc. (NASDAQ:NAKA - Free Report) - Stock analysts at Maxim Group issued their Q2 2026 earnings per share (EPS) estimates for shares of KindlyMD in a report issued on Wednesday, May 27th. Maxim Group analyst M. Galinko forecasts that the company will earn ($0.41) per share for the quarter. Maxim Group has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for KindlyMD's current full-year earnings is ($16.80) per share. Maxim Group also issued estimates for KindlyMD's Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.60) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.88) EPS, Q3 2027 earnings at $0.72 EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.44) EPS.

KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($15.20) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.The firm had revenue of $2.68 million during the quarter.

NAKA has been the subject of several other research reports. Wall Street Zen raised KindlyMD to a "sell" rating in a research note on Saturday, May 23rd. TD Cowen assumed coverage on KindlyMD in a research note on Friday, April 10th. They issued a "buy" rating and a $40.00 price target for the company. B. Riley Financial decreased their price target on KindlyMD from $40.00 to $20.00 and set a "buy" rating for the company in a research note on Monday, February 23rd. Finally, Weiss Ratings raised KindlyMD from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, May 11th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $30.00.

KindlyMD Stock Up 3.7%

Shares of NAKA opened at $5.60 on Friday. KindlyMD has a 12-month low of $4.50 and a 12-month high of $995.60. The business has a 50-day simple moving average of $8.21 and a two-hundred day simple moving average of $13.07. The stock has a market cap of $97.44 million, a PE ratio of -0.13 and a beta of 17.12.

Insider Buying and Selling

In other KindlyMD news, CEO David F. Bailey bought 55,115 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average price of $5.62 per share, with a total value of $309,746.30. Following the completion of the purchase, the chief executive officer directly owned 3,175,476 shares of the company's stock, valued at approximately $17,846,175.12. This trade represents a 1.77% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders purchased a total of 191,448 shares of company stock worth $992,908 over the last ninety days. Company insiders own 24.49% of the company's stock.

Institutional Investors Weigh In On KindlyMD

Several large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company's stock worth $484,000 after purchasing an additional 8,386 shares during the period. Osaic Holdings Inc. acquired a new stake in KindlyMD during the second quarter worth approximately $215,000. Dynamic Technology Lab Private Ltd bought a new position in KindlyMD in the third quarter worth approximately $369,000. Tower Research Capital LLC TRC boosted its holdings in KindlyMD by 1,638.4% in the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company's stock worth $827,000 after acquiring an additional 31,245 shares in the last quarter. Finally, CI Investments Inc. bought a new position in KindlyMD in the third quarter worth approximately $995,000.

KindlyMD News Roundup

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 104,833 shares at an average price of $4.84, adding to a series of recent open-market purchases and lifting his ownership stake, which may reassure investors about management’s confidence in KindlyMD. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating and $30 price target, with forecasted improvement in later-period earnings, which could help support sentiment around NAKA. Article Title
• Neutral Sentiment: Maxim’s earnings estimates still call for losses in the near term, but they model a shift to profitability in some periods of fiscal 2027, suggesting the turnaround story remains speculative. Article Title
• Negative Sentiment: The company’s latest reported quarter showed a large EPS loss and weak profitability metrics, which continue to highlight execution risk for investors. Article Title

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.